Evidence map›Paper›PMID 11313936›Full record

ArticleOncogene2001

The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters.

R J O'Connor, J E Schaley, G Feeney, P Hearing

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Identification of E2F1 as a positive transcriptional regulator for delta-catenin.Biochemical and biophysical research communications · 2008
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

R J O'ConnorDepartment of Molecular Genetics and Microbiology, School of Medicine, State University of New York, Stony Brook, New York, NY 11794, USA.
J E Schaley
G Feeney
P Hearing
State University of New York · US

Funding

TUMOR VIRUS-HOST INTERACTIONSP01CA028146 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI HEARING, PATRICK · 1986 to 2005
$9.9M
NCI NIH HHS CA09176NCI NIH HHS CA28146
6 · The paper itself

Abstract

E2F transcription factors are key players in the regulation of proliferation, apoptosis, and differentiation in mammalian cells. E2Fs are negatively regulated by members of the retinoblastoma protein family, Rb, p107 and p130. During adenovirus infection, viral proteins are expressed that displace Rb family members from E2Fs and recruit E2F complexes to viral and cellular promoter regions. This recruitment of E2F involves the induction of stable E2F binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters and induces both viral and cellular gene expression. The cellular p107 tumor suppressor also displays such regulation of E2F DNA binding activity. p107 induces stable E2F-4/DP binding to inverted E2F binding sites in the Ad E2a and cellular E2F-1 promoters. The induction of E2F DNA binding by p107 minimally requires the sequences in p107 that mediate E2F interaction. The related tumor suppressor, p130, also effects this function. p107 levels increase substantially as cells progress through S phase. p107 induction of E2F DNA binding was observed primarily in S phase cells coincident with the increase in p107 protein levels. The results of promoter activity assays directly correlate the induction of E2F DNA binding by p107 with effective transcriptional repression. These results support a model in which p107 and p130 induce the stable binding of E2F complexes to promoters that drive expression of critical regulatory proteins such as E2F-1. Since p107 and p130 bind histone deacetylase complexes (HDACs) which repress promoter activity, p107-E2F and p130-E2F would stably recruit repressor complexes to effect efficient promoter repression.

Indexed as

Carrier ProteinsCell Cycle ProteinsDNA-Binding ProteinsPromoter Regions, GeneticProteinsBinding SitesCell LineDNAE2F1 Transcription FactorE2F4 Transcription FactorE2F Transcription FactorsHumansNuclear ProteinsPhosphoproteinsRetinoblastoma-Binding Protein 1Retinoblastoma-Like Protein p107Carrier ProteinsCell Cycle ProteinsDNADNA-Binding ProteinsE2F1 protein, humanE2F1 Transcription FactorE2F4 protein, humanE2F4 Transcription FactorE2F Transcription FactorsNuclear ProteinsPhosphoproteinsProteinsRBL1 protein, humanRBL2 protein, humanRetinoblastoma-Binding Protein 1Retinoblastoma-Like Protein p107Retinoblastoma-Like Protein p130Transcription Factor DP1Transcription Factors

Identifiers

PMID11313936
OpenAlexW2324912202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.